The Latest Breaking News from BristolMyers Squibb

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 12 strange trades.

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 8.98% since its last report. The company recently reported that it has 32.18 million shares sold short, which is 1.52% of all regular shares that are available for trading.

A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 25 strange trades.

Upgrades

Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings within the last quarter:

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and…

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 10.76% since its last report. The company recently reported that it has 42.24 million shares sold short, which is 1.99% of all regular shares that are available for trading.